Open label phase 3b, 48 wk pilot study of the antiviral efficacy and tolerability of combination of Prezista [darunavir]/r [ritonavir] and TMC125 [etravirine] when substituted for enfuvirtide, current protease inhibitor(s) and NNRTI(s) in antiretroviral resistant patients with viral suppression but who are intolerant of enfuvirtide

Trial Profile

Open label phase 3b, 48 wk pilot study of the antiviral efficacy and tolerability of combination of Prezista [darunavir]/r [ritonavir] and TMC125 [etravirine] when substituted for enfuvirtide, current protease inhibitor(s) and NNRTI(s) in antiretroviral resistant patients with viral suppression but who are intolerant of enfuvirtide

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Jul 2013

At a glance

  • Drugs Darunavir; Etravirine; Ritonavir
  • Indications HIV infections
  • Focus Therapeutic Use
  • Sponsors Tibotec Inc
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 08 Apr 2009 Actual patient numbers added 10 as reported by ClinicalTrials.gov.
    • 08 Apr 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top